Adynxx, a newly-formed clinical stage pharmaceutical company developing therapeutics addressing pain at its molecular roots, emerged from stealth mode this week with the announcement that it has completed enrollment in a Phase 1 clinical study of its lead therapeutic for pain, AYX1.
The 30-subject, dose-escalating study is currently evaluating AYX1 in five cohorts of healthy volunteers. Later this year, Adynxx plans to move into a proof-of-concept Phase 2 clinical study assessing the ability of a single administration of AYX1 at the time of surgery to reduce acute pain, prevent the transition to persistent post-surgical pain and consequently improve functional recovery.
In a variety of preclinical pain and functional assessment models, long-term efficacy of AYX1 after a single administration has been demonstrated. In addition to AYX1, Adynxx is advancing a pipeline of therapeutics for the treatment of other indications, including chronic lower back pain and intractable neuropathic and inflammatory pain syndromes.
Russo Partners worked with Adynxx to develop key messages surrounding the announcement and secured coverage of the news in trade as well as regional publications.
Read more about the company and its programs in the articles below from Xconomy and the San Francisco Business Times.